This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- 18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use
- 18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use
- Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
- Treatment Outcomes in Neuroendocrine Prostate Cancer
- Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas
- Somatostatin Receptor Scintigraphy: Blazing in Indium and Quenching in Gallium (perspective on "Somatostatin Receptor Scintigraphy with Indium-111-DTPA-D-Phe-1-Octreotide in Man: Metabolism, Dosimetry and Comparison with Iodine-123-Tyr-3-Octreotide" J Nucl Med. 1992;33:652-658)
- International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
- A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting
- Somatostatin Receptor 2-Targeting Compounds
- Management of neuroendocrine tumors
- Evaluation of a Fluorescent and Radiolabeled Hybrid Somatostatin Analog In Vitro and in Mice Bearing H69 Neuroendocrine Xenografts
- 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
- Optimized Peptide Amount and Activity for 90Y-Labeled DOTATATE Therapy
- 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients
- Preclinical SPECT/CT Imaging of {alpha}v{beta}6 Integrins for Molecular Stratification of Idiopathic Pulmonary Fibrosis
- Measured Human Dosimetry of 68Ga-DOTATATE
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- Patient-Specific Dosimetry Calculations Using Mathematic Models of Different Anatomic Sizes During Therapy with 111In-DTPA-D-Phe1-Octreotide Infusions After Catheterization of the Hepatic Artery
- Gluc-Lys([18F]FP)-TOCA PET in Patients with SSTR-Positive Tumors: Biodistribution and Diagnostic Evaluation Compared with [111In]DTPA-Octreotide
- Monitoring of Bone Marrow Cell Homing Into the Infarcted Human Myocardium
- Therapeutic Efficacy of a 188Re-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptide Analog in Murine and Human Melanoma-Bearing Mouse Models
- Long-Term Efficacy of Radionuclide Therapy in Patients with Disseminated Neuroendocrine Tumors Uncontrolled by Conventional Therapy
- Uptake of [111In-DTPA0]Octreotide in the Rat Kidney Is Inhibited by Colchicine and Not by Fructose
- 110mIn-DTPA-D-Phe1-Octreotide for Imaging of Neuroendocrine Tumors with PET
- 64Cu-TETA-Octreotide as a PET Imaging Agent for Patients with Neuroendocrine Tumors
- Somatostatin Receptor Scintigraphy in the Initial Staging of Low-Grade Non-Hodgkin's Lymphomas
- Value of Peptide Receptor Scintigraphy Using 123I-Vasoactive Intestinal Peptide and 111In-DTPA-D-Phe1-Octreotide in 194 Carcinoid Patients: Vienna University Experience, 1993 to 1998
- Radiotherapy and Dosimetry of 64Cu-TETA-Tyr3-Octreotate in a Somatostatin Receptor-positive, Tumor-bearing Rat Model
- In Vivo Localization of [111In]-DTPA-D-Phe -Octreotide to Human Ovarian Tumor Xenografts Induced to Express the Somatostatin Receptor Subtype 2 Using an Adenoviral Vector
- Design and characterization of {alpha}-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination
- Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study
- Somatostatin Receptors in the Diagnosis and Therapy of Neuroendocrine Tumors